Bill117th CongressFiled May 18, 2022Health
H.R. 7828
PRICED Act
Bill journey · stage 2 of 5
Under committee review
FiledFiled
CommitteeComm.
PassedFloor
Both ChambersBoth
Became LawLaw
What it doesSummary introduced in house (May 18, 2022)
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.
This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.
What just happenedMay 18, 2022
Referred to the House Committee on Energy and Commerce.
Who’s behind it
Rep. Schakowsky, Janice D. [D-IL-9](D-IL)Sponsor
10 cosponsors9 D1 R
10cosponsors1committees3actions2related bills
- Introduced in HouseMay 18, 2022
- May 18, 2022IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - May 18, 2022IntroReferralIntro-H
Introduced in House
- May 18, 2022IntroReferral1000
Introduced in House